Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 Jan 11

PMID 33425894

Citations 7

Authors

Audrey Laurain

Isabelle Rubera

Christophe Duranton

Frank Rutsch

Yvonne Nitschke

Elodie Ray

Sandor Vido

Antoine Sicard

Georges Leftheriotis

Guillaume Favre

Affiliations

Soon will be listed here.

Abstract

Introduction: Patients on dialysis and kidney transplant recipients (KTR) present the syndrome of mineral and bone disorders (MBD), which share common traits with monogenic calcifying diseases related to disturbances of the purinergic system. Low plasma levels of inorganic pyrophosphate (PP) and ectopic vascular calcifications belong to these two conditions. This suggests that the purinergic system may be altered in chronic kidney disease with MBD. Therefore, we perform a transversal pilot study in order to compare the determinants of PPi homeostasis and the plasma levels of PPi in patients on dialysis, in KTR and in healthy people.

Patients And Methods: We included 10 controls, 10 patients on maintenance dialysis, 10 early KTR 3 ± 1 months after transplantation and nine late KTR 24 ± 3 months after transplantation. We measured aortic calcifications, plasma and urine levels of PP, the renal fractional excretion of PP (FePP), nucleoside triphosphate hydrolase (NPP) and ALP activities in plasma. Correlations and comparisons were assessed with non-parametric tests.

Results: Low PP was found in patients on dialysis [1.11 (0.88-1.35), = 0.004], in early KTR [0.91 (0.66-0.98), = 0.0003] and in late KTR [1.16 (1.07-1.45), = 0.02] compared to controls [1.66 (1.31-1.72) μmol/L]. Arterial calcifications were higher in patients on dialysis than in controls [9 (1-75) vs. 399 (25-526) calcium score/cm, < 0.05]. ALP activity was augmented in patients on dialysis [113 (74-160), = 0.01] and in early KTR [120 (84-142), = 0.002] compared to controls [64 (56-70) UI/L]. The activity of NPP and FePP were not different between groups. ALP activity was negatively correlated with PP ( = -0.49, = 0.001).

Discussion: Patients on dialysis and KTR have low plasma levels of PP, which are partly related to high ALP activity, but neither to low NPP activity, nor to increased renal excretion of PP. Further work is necessary to explore comprehensively the purinergic system in chronic kidney disease.

Citing Articles

The PROPHECI trial: a phase II, double-blind, placebo-controlled, randomized clinical trial for the treatment of pseudoxanthoma elasticum with oral pyrophosphate.

Clotaire L, Rubera I, Duranton C, Gal J, Chamorey E, Humeau H Trials. 2025; 26(1):30.

PMID: 39881395 PMC: 11776210. DOI: 10.1186/s13063-024-08666-w.

Oral pyrophosphate protects Abcc6 mice against vascular calcification induced by chronic kidney disease.

Bouderlique E, Kervadec J, Tang E, Zaworski J, Coudert A, Rubera I J Mol Med (Berl). 2024; 102(10):1217-1227.

PMID: 39136767 DOI: 10.1007/s00109-024-02468-y.

Arterial Calcifications in Patients with Liver Cirrhosis Are Linked to Hepatic Deficiency of Pyrophosphate Production Restored by Liver Transplantation.

Laurain A, Rubera I, Razzouk-Cadet M, Bonnafous S, Albuquerque M, Paradis V Biomedicines. 2022; 10(7).

PMID: 35884801 PMC: 9312703. DOI: 10.3390/biomedicines10071496.

Relationships between Plasma Pyrophosphate, Vascular Calcification and Clinical Severity in Patients Affected by Pseudoxanthoma Elasticum.

Leftheriotis G, Navasiolava N, Clotaire L, Duranton C, Le Saux O, Bendahhou S J Clin Med. 2022; 11(9).

PMID: 35566717 PMC: 9100273. DOI: 10.3390/jcm11092588.

The Role of Purinergic Signaling in Heart Transplantation.

Jiang Y, Lin J, Zheng H, Zhu P Front Immunol. 2022; 13:826943.

PMID: 35529844 PMC: 9069525. DOI: 10.3389/fimmu.2022.826943.

References

Villa-Bellosta R, Gonzalez-Parra E, Egido J . Alkalosis and Dialytic Clearance of Phosphate Increases Phosphatase Activity: A Hidden Consequence of Hemodialysis. PLoS One. 2016; 11(7):e0159858. PMC: 4959680. DOI: 10.1371/journal.pone.0159858. View

Wallace B, Lott J, Griffiths J, Kirkpatrick R . Isoforms of alkaline phosphatase determined by isoelectric focusing in patients with chronic liver disorders. Eur J Clin Chem Clin Biochem. 1996; 34(9):711-20. DOI: 10.1515/cclm.1996.34.9.711. View

Fernley H, Walker P . Studies on alkaline phosphatase. Inhibition by phosphate derivatives and the substrate specificity. Biochem J. 1967; 104(3):1011-8. PMC: 1271245. DOI: 10.1042/bj1041011. View

Tani T, Fujiwara M, Orimo H, Shimizu A, Narisawa S, Pinkerton A . Inhibition of tissue-nonspecific alkaline phosphatase protects against medial arterial calcification and improves survival probability in the CKD-MBD mouse model. J Pathol. 2019; 250(1):30-41. PMC: 7238767. DOI: 10.1002/path.5346. View

Netter P, Bardin T, Bianchi A, Richette P, Loeuille D . The ANKH gene and familial calcium pyrophosphate dihydrate deposition disease. Joint Bone Spine. 2004; 71(5):365-8. DOI: 10.1016/j.jbspin.2004.01.011. View

Kurz P, Monier-Faugere M, Bognar B, Werner E, Roth P, Vlachojannis J . Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994; 46(3):855-61. DOI: 10.1038/ki.1994.342. View

Bover J, Urena P, Aguilar A, Mazzaferro S, Benito S, Lopez-Baez V . Alkaline Phosphatases in the Complex Chronic Kidney Disease-Mineral and Bone Disorders. Calcif Tissue Int. 2018; 103(2):111-124. DOI: 10.1007/s00223-018-0399-z. View

Agatston A, Janowitz W, HILDNER F, Zusmer N, VIAMONTE Jr M, Detrano R . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15(4):827-32. DOI: 10.1016/0735-1097(90)90282-t. View

Favre G, Laurain A, Aranyi T, Szeri F, Fulop K, Le Saux O . The ABCC6 Transporter: A New Player in Biomineralization. Int J Mol Sci. 2017; 18(9). PMC: 5618590. DOI: 10.3390/ijms18091941. View

10.

Zhao G, Xu M, Zhao M, Dai X, Kong W, Wilson G . Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. Kidney Int. 2012; 82(1):34-44. PMC: 3376207. DOI: 10.1038/ki.2012.40. View

11.

Lau W, Liu S, Vaziri N . Chronic kidney disease results in deficiency of ABCC6, the novel inhibitor of vascular calcification. Am J Nephrol. 2014; 40(1):51-5. DOI: 10.1159/000365014. View

12.

Rutsch F, Ruf N, Vaingankar S, Toliat M, Suk A, Hohne W . Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet. 2003; 34(4):379-81. DOI: 10.1038/ng1221. View

13.

Whyte M . Hypophosphatasia: An overview For 2017. Bone. 2017; 102:15-25. DOI: 10.1016/j.bone.2017.02.011. View

14.

Chiu Y, Adler S, Budoff M, Takasu J, Ashai J, Mehrotra R . Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int. 2010; 77(12):1107-14. DOI: 10.1038/ki.2010.70. View

15.

Wolf M, Weir M, Kopyt N, Mannon R, Visger J, Deng H . A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation. 2015; 100(1):184-93. PMC: 4683035. DOI: 10.1097/TP.0000000000000823. View

16.

Ketteler M, Block G, Evenepoel P, Fukagawa M, Herzog C, McCann L . Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017; 92(1):26-36. DOI: 10.1016/j.kint.2017.04.006. View

17.

Lomashvili K, Khawandi W, ONeill W . Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol. 2005; 16(8):2495-500. DOI: 10.1681/ASN.2004080694. View

18.

Le Saux O, Urban Z, Tschuch C, Csiszar K, Bacchelli B, Quaglino D . Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet. 2000; 25(2):223-7. DOI: 10.1038/76102. View

19.

Mitton-Fitzgerald E, Gohr C, Bettendorf B, Rosenthal A . The Role of ANK in Calcium Pyrophosphate Deposition Disease. Curr Rheumatol Rep. 2016; 18(5):25. PMC: 5453179. DOI: 10.1007/s11926-016-0574-z. View

20.

Haarhaus M, Brandenburg V, Kalantar-Zadeh K, Stenvinkel P, Magnusson P . Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD. Nat Rev Nephrol. 2017; 13(7):429-442. DOI: 10.1038/nrneph.2017.60. View